CVOT crossroads

Why patients, doctors want FDA to revisit its 2008 diabetes CV guidance

As data begin to trickle in from the wave of cardiovascular outcomes trials mandated in the wake of the Avandia rosiglitazone debacle, patients, physicians and some of FDA's own advisory committee members think the agency should either scrap the requirement for outcomes studies, or refocus them on issues that matter to patients and physicians.

On April 14, FDA's Endocrinologic and Metabolic Drugs Advisory Committee met to discuss results from the SAVOR and EXAMINE cardiovascular outcomes trials of the DPP-4 inhibitors Onglyza saxagliptin from AstraZeneca plc and Nesina alogliptin from Takeda Pharmaceutical Co. Ltd.

SAVOR and EXAMINE are the first two cardiovascular outcomes trials (CVOTs) completed under FDA's 2008 guidance that requires companies with diabetes drugs to rule out at least a 30% increase in the risk of major adverse cardiac events (MACE) after approval.

The guidance was issued after a 2007 meta-analysis by cardiologist Steven Nissen and epidemiologist Kathy Wolski at the Cleveland Clinic concluded there was an increased risk of myocardial infarction (MI) and CV mortality for patients treated with GlaxoSmithKline plc's Avandia. Readjudicated data from the RECORD outcomes study exonerated Avandia, yet the guidance remains.

Onglyza and

Read the full 1900 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers